Enter multiple symbols separated by commas

Glaxo Says New Study Shows No Avandia Heart Risk

A new study of health insurance records of more than 400,000 U.S. diabetics found no higher risk of heart attacks with GlaxoSmithKline'spill Avandia when compared with other oral diabetes drugs, the drugmaker said in documents made public Thursday.

The study also showed no higher rate of coronary revascularization procedures, such as bypass surgery, in patients who took Avandia, the company said.

Glaxo funded the study, which was done by researchers at i3 Drug Safety, a division of health information company Ingenix.

The findings were included in a summary Glaxo provided to the Food and Drug Administration, which is holding an advisory panel meeting on Monday to evaluate Avandia's heart risks.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Earnings will be a nail biter: Jack Ablin

    Jack Ablin, BMO Private Bank CIO, provides perspective on current trading action, and what's to come from earnings.

  • Tale of two Chinas

    How can traders cash in on the fall in China's market, with Stacey Gilbert, Susquehanna, and Boris Schlossberg, BK Asset Management.

  • Greeks on the verge of panic

    CNBC's Michelle Caruso-Cabrera speaks to Greek pharmacist George Bacacos, about what is to come for Greece.